Descrição AVI BioPharma has a sixth sense about antisense. A developer of biopharmaceutical compounds, the company's investigational therapies are based on its antisense drug technology, which can halt disease processes at the genetic level. The drug developer is working on drugs that could potentially be used in the treatment of a wide range of conditions, including genetic and infectious diseases. AVI BioPharma's had research and development programs for targets including muscular dystrophy, hepatitis C, pandemic influenza, the Ebola virus, and Dengue fever.